SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity

W Zheng, Z Yang, P Song, Y Sun, P Liu, L Yue, K Lv… - Cancer Letters, 2023 - Elsevier
Despite the promising antitumor activity of RAF/MEK inhibitors for RAS-driven cancers, not
all patients respond to these therapies. Adaptive resistance has been reported as a major …
被引用次数：5 相关文章

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.

W Zheng, Z Yang, P Song, Y Sun, P Liu, L Yue, K Lv… - Cancer Letters, 2022 - europepmc.org
Despite the promising antitumor activity of RAF/MEK inhibitors for RAS-driven cancers, not
all patients respond to these therapies. Adaptive resistance has been reported as a major …

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity

W Zheng, Z Yang, P Song, Y Sun, P Liu… - Cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Despite the promising antitumor activity of RAF/MEK inhibitors for RAS-driven cancers, not
all patients respond to these therapies. Adaptive resistance has been reported as a major …